Interferon-gamma increases the expression of glycosylated CD95 in B-leukemic cells: an inducible model to study the role of glycosylation in CD95-signalling and trafficking.
B-lineage acute leukaemia cells are generally resistant to CD95-mediated apoptosis. In this report, the CD95-resistant B-leukaemia lines SEM, RS4;11, and REH were used to investigate the mechanisms of resistance to CD95-signalling. We found that interferon-gamma (IFN-gamma) treatment increased the presence of high molecular weight forms of CD95 in these cells as judged by Western analysis, and treatment of protein extracts with Peptide: N -glycosidase F indicated that the majority of high molecular weight forms were due to N-linked glycosylation. Treatment of whole cells with neuraminidase from Vibrio cholerae substantially reduced the relative molecular mass of CD95 observed after IFN-gamma treatment and partially sensitized the three leukaemia lines to CD95-mediated death. To further characterize the different steps of oligosaccharide processing that may regulate CD95 signalling, the leukaemic cells were treated with IFN-gamma and the glycosidase inhibitors castanospermine, 1-deoxymannojirimycin (DMM), and swainsonine. Treatment with DMM, a mannosidase inhibitor, efficiently reduced the appearance of high molecular weight forms of CD95 after IFN-gamma treatment, and sensitized SEM and REH cells to CD95-mediated death. However, the IFN-gamma-induced increases of CD95 on the cell surface were not altered by treatment with any of the glycosidase inhibitors, suggesting that the generation of complex oligosaccharide structures is not required for trafficking of CD95, but may instead be used as a mechanism of partially blocking CD95 signalling in these cells. In conclusion, IFN-gamma treatment of the B-lineage leukaemia lines provides a novel, inducible system for the further characterization of post-translational modifications involved in modulating sensitivity to CD95-signalling.
Dörrie
Jan
J
Chair of Genetics, Friedrich-Alexander University of Erlangen-Nürnberg, Staudtstr. 5, Erlangen, D91058, Germany.
Sapala
Katrin
K
Zunino
Susan J
SJ
D017485:1-Deoxynojirimycin / Q000494:pharmacology; D016923:Cell Death; D002462:Cell Membrane / Q000276:immunology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006026:Glycoside Hydrolases / Q000037:antagonists & inhibitors; D006031:Glycosylation; D006801:Humans; D007212:Indolizines / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology*; D015448:Leukemia, B-Cell; D008954:Models, Biological; D008970:Molecular Weight; D009439:Neuraminidase / Q000494:pharmacology; D009844:Oligosaccharides / Q000494:pharmacology; D011499:Protein Processing, Post-Translational; D015398:Signal Transduction / Q000502:physiology*; D017026:Swainsonine / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014734:Vibrio cholerae / Q000201:enzymology; D019014:fas Receptor / Q000378:metabolism*; D054836:Indolizidines
D017485:1-Deoxynojirimycin; D004791:Enzyme Inhibitors; D006026:Glycoside Hydrolases; D007212:Indolizines; D007371:Interferon-gamma; D009439:Neuraminidase; D009844:Oligosaccharides; D017026:Swainsonine; D019014:fas Receptor; C037806:castanospermine; D054836:Indolizidines